Ren Tao-wen, Zhou Yong-ning, Wu Jing, Zhang Zhi-yi, Hao Tian-jun, Wang Juan-xia, Zou Shao-jing, Chen Zhao-feng, Huang Shan-Shan, Zhang Li-Hua, Zhao Yue
Department of Gastroenterology of the First Hospital of Lanzhou University, Lanzhou, China.
Zhonghua Zhong Liu Za Zhi. 2009 Sep;31(9):674-8.
To investigate the expression of Ets-1 in gastric carcinoma, para-cancerous tissue and metastatic lymph nodes, and to determine the relationship between Ets-1 expression and clinicopathological features, angiogenesis and survival of patients with gastric carcinoma.
Gastric carcinoma tissue microarray was used to determine Ets-1 protein expression by SP immunohistochemical staining in 189 advanced gastric cancer, 54 papacancerous tissues, 41 metastatic lymph nodes and 32 control tissues.
The positive rates for Ets-1 expression of the carcinoma, paracancerous and control tissues were 71.4%, 29.6% and 18.8%, respectively, with a significant difference among the three groups (P < 0.01). In the cancer tissues, the positive rate of Ets-1 protein expression was significantly associated with depth of invasion and lymph node metastasis (P < 0.01), but not associated with degree of differentiation, Lauren's histological type, sex, age, and size of tumor (P > 0.05). The positive rates for Ets-1 expression of the 41 gastric cancer and 41 metastatic lymph nodes were significantly different (P < 0.05). In metastatic lymph nodes, the positive rate for Ets-1 expression was higher. The MVD in Ets-1 positive tumors was higher than that in the Ets-1 negative tumors, with a significant difference (P < 0.05). Kaplan-Meier survival analysis showed that the survival time of Ets-1-negative patients was longer than that of Ets-1-positive patients (P < 0.05). Cox regression analysis showed that Ets-1 expression was not an independent prognostic factor of gastric carcinoma.
A higher expression of Ets-1 is involved in carcinogenesis, development, invasion, and metastasis of gastric cancer. Ets-1 plays an important role in angiogenesis in gastric cancer. Ets-1 is a useful marker for predicting the outcome for patients with gastric carcinoma, though it is not an independent prognostic indicator.
研究Ets-1在胃癌、癌旁组织及转移淋巴结中的表达情况，明确Ets-1表达与胃癌患者临床病理特征、血管生成及生存的关系。
采用胃癌组织芯片，通过SP免疫组化染色检测189例进展期胃癌、54例癌旁组织、41例转移淋巴结及32例对照组织中Ets-1蛋白的表达。
癌组织、癌旁组织及对照组织中Ets-1表达的阳性率分别为71.4%、29.6%和18.8%，三组间差异有统计学意义（P<0.01）。在癌组织中，Ets-1蛋白表达阳性率与浸润深度和淋巴结转移显著相关（P<0.01），但与分化程度、Lauren组织学类型、性别、年龄及肿瘤大小无关（P>0.05）。41例胃癌组织和41例转移淋巴结中Ets-1表达的阳性率差异有统计学意义（P<0.05）。在转移淋巴结中，Ets-1表达的阳性率更高。Ets-1阳性肿瘤中的微血管密度高于Ets-1阴性肿瘤，差异有统计学意义（P<0.05）。Kaplan-Meier生存分析显示，Ets-1阴性患者的生存时间长于Ets-1阳性患者（P<0.05）。Cox回归分析显示，Ets-1表达不是胃癌的独立预后因素。
Ets-1的高表达参与胃癌的发生、发展、浸润和转移。Ets-1在胃癌血管生成中起重要作用。Ets-1是预测胃癌患者预后的有用标志物，尽管它不是独立的预后指标。
